NICE Clears Teplizumab for Early Type 1 Diabetes, Delaying Insulin by 2-3 Years
Updated
Updated · diabetes.org.uk · Jun 23
NICE Clears Teplizumab for Early Type 1 Diabetes, Delaying Insulin by 2-3 Years
3 articles · Updated · diabetes.org.uk · Jun 23
Summary
NICE approved teplizumab for NHS use in England and Wales for people aged 8 and over with symptomless early-stage type 1 diabetes whose blood sugar has begun to rise.
A landmark trial showed the immunotherapy delayed progression to insulin-treated disease by an average of two to three years by protecting remaining beta cells and resetting the immune attack.
NHS England now has 90 days to set up access, while Wales has 60 days; Scotland and Northern Ireland will decide separately through their own review processes.
Eligibility depends on early detection through type 1 diabetes autoantibody testing, with UK screening studies already covering children aged 2-17 and adults aged 18-70.
The approval marks a shift from treating symptoms after diagnosis to intervening before insulin is needed, potentially reducing emergency diabetic ketoacidosis and widening the push for national screening.
Is a three-year diabetes delay worth a £150,000 price tag, and can public health systems truly afford this breakthrough?
How will the NHS identify at-risk children for its new diabetes drug without a national screening program in place?
Beyond just delaying diabetes, could new immune and stem cell therapies finally end the need for daily insulin injections?
Delaying Type 1 Diabetes: The Promise and Challenges of Teplizumab Rollout in the UK NHS
Overview
Teplizumab’s recent licensing in the UK marks a major step forward in delaying type 1 diabetes by up to three years, as it targets the disease’s root cause. However, for this breakthrough to benefit patients, several key steps must follow: the drug needs to be assessed by NICE for NHS funding, and a national screening program must be established to identify eligible individuals early. The report highlights that without these measures and the necessary healthcare infrastructure, teplizumab cannot become widely accessible, making coordinated action essential to turn scientific progress into real-world impact.